Phase 1 Leukemia/Lymphoma Clinical Trials
9 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–9 of 9 trials
Recruiting
Phase 1Phase 2
A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma
Adult T-Cell Leukemia/Lymphoma (ATLL)
Otsuka Medical Devices Co., Ltd. Japan49 enrolled5 locationsNCT07075328
Recruiting
Phase 1
U69-CART-Cells For R/R T-ALL
Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
The First Affiliated Hospital of Soochow University12 enrolled1 locationNCT07350863
Recruiting
Phase 1
Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma
Recurrent Adult T-Cell Leukemia/LymphomaRecurrent Primary Cutaneous T-Cell Non-Hodgkin LymphomaRefractory Adult T-Cell Leukemia/Lymphoma+1 more
John Reneau12 enrolled1 locationNCT04848064
Recruiting
Phase 1
Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
T-Cell Acute Lymphoblastic Leukemia/Lymphoma
Stephan Grupp MD PhD33 enrolled1 locationNCT06934382
Recruiting
Phase 1Phase 2
SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
Acute Myeloid Leukemia (AML)T Lymphoblastic Leukemia/Lymphoma
Institute of Hematology & Blood Diseases Hospital, China12 enrolled1 locationNCT07153068
Recruiting
Phase 1
uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
Acute Myeloid Leukemia (AML)T Lymphoblastic Leukemia/Lymphoma
Institute of Hematology & Blood Diseases Hospital, China12 enrolled1 locationNCT07109518
Recruiting
Phase 1
CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies
Acute Myeloid LeukemiaB Acute Lymphoblastic Leukemia/Lymphoma
Institute of Hematology & Blood Diseases Hospital, China12 enrolled1 locationNCT07106749
Recruiting
Phase 1Phase 2
CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors
B-Cell Lymphoblastic Leukemia/Lymphoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology80 enrolled1 locationNCT06735495
Recruiting
Phase 1Phase 2
CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors
B-Cell Lymphoblastic Leukemia/Lymphoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology80 enrolled1 locationNCT06503094